Search

Your search keyword '"Hamasaki, Keisuke"' showing total 260 results
Start Over Author "Hamasaki, Keisuke"
260 results on '"Hamasaki, Keisuke"'

5. Non‐liver‐related mortality in the DAA era: Insights from post‐SVR patients with and without previous HCC history.

Author

Miuma, Satoshi, Miyaaki, Hisamitsu, Ichikawa, Tatsuki, Matsuzaki, Toshihisa, Goto, Takashi, Kamo, Yasuhiro, Shigeno, Masaya, Hino, Naoyuki, Ario, Keisuke, Yanagi, Kenji, Tsutsumi, Takuya, Fukushima, Nobuyoshi, Nakashiki, Suguru, Yamasaki, Kazufumi, Hamasaki, Keisuke, Shibata, Hidetaka, Arima, Kazuhiko, Yamamichi, Shinobu, Yamashima, Mio, and Takahashi, Kosuke

Subjects
DEATH rate, MORTALITY, CAUSES of death, PATIENT care
Abstract

Background and Aims: Mortality after sustained virological response (SVR) with interferon‐free direct‐acting antiviral (IFN‐free DAA) therapy is crucial for optimizing post‐SVR patient care, but it remains unclear, especially regarding non‐liver‐related mortality. Methods: Consecutive post‐SVR patients from 14 institutions were stratified into three cohorts: A (without advanced fibrosis and without prior HCC), B (with advanced fibrosis and without prior HCC), and C (curative HCC treatment). We assessed mortality (per 1000 person‐years [/1000PY]) post‐SVR. Mortality rates were compared between cohorts A and B and the general population using age‐ and sex‐adjusted standardized mortality ratio (SMR). Comparison of survival between each cohort was performed using propensity‐score (PS) matching with sex, age, and comorbidity. Results: In cohort A (n = 762; median age, 65 years), 22 patients died (median follow‐up, 36 months); all‐cause mortality was 10.0/1000PY, with 86.4% non‐liver‐related deaths. In cohort B (n = 519; median age, 73 years), 27 patients died (median follow‐up, 39 months); all‐cause mortality was 16.7/1000PY, with 88.9% non‐liver‐related deaths. In both cohorts, malignant neoplasm was the most common cause of death; all‐cause mortality was comparable to that of the general population (SMR: 0.96 and 0.92). In cohort C (n = 108; median age, 75 years), 15 patients died (median follow‐up, 51 months); all‐cause mortality was 36.0/1000PY, with 53.3% liver‐related deaths. PS matching showed no significant survival differences between cohorts A and B, both of which had better survival than cohort C. Conclusions: Mortality varies based on HCC history in the DAA era; nevertheless, attention should be paid to non‐liver‐related deaths in all post‐SVR patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Anti-hepatitis C virus activity of geranylgeranylacetone treatment in hepatitis C-infected patients

Author

Yamaguchi, Tohei, Ichikawa, Tatsuki, Takeshita, Shigeyuki, Taura, Naota, Miyaaki, Hisamitsu, Muraoka, Toru, Shibata, Hidetaka, Honda, Takuya, Hamasaki, Keisuke, Kato, Yuji, Takeshima, Fuminao, Nakao, Kazuhiko, Yamaguchi, Tohei, Ichikawa, Tatsuki, Takeshita, Shigeyuki, Taura, Naota, Miyaaki, Hisamitsu, Muraoka, Toru, Shibata, Hidetaka, Honda, Takuya, Hamasaki, Keisuke, Kato, Yuji, Takeshima, Fuminao, and Nakao, Kazuhiko

Abstract

Background. Geranylgeranylacetone (GGA), which is an isoprenoid compound, has been used orally as an antiulcer drug inJapan. GGA induces antiviral gene expression by stimulating the formation of interferon-stimulated gene factor 3 in humanhepatoma cells. This study verified the anti-hepatitis C virus (HCV) activity of GGA in chronic hepatitis C-infected patients.Methods. The present prospective study included 20 consecutive anti-HCV antibody-positive, HCV-genotype 1b, and chronicgastritis patients who visited Nagasaki University Hospital between January 1999 and December 1999. GGA (150 mg per day,which is the dose generally used for chronic gastritis) was taken orally for four weeks. We evaluated HCV-RNA titers and otherclinical parameters at pretreatment, posttreatment, and at the endpoint of the study. Pretreatment was the beginning point ofGGA treatment. Posttreatment was the termination point of GGA treatment. The endpoint was the point four weeks after theposttreatment point.Results. All patients completed four weeks of GGA treatment and four weeks of observation. HCV-RNA titers at postpointwere not significantly diminished compared to those at pretreatment. However, HCV-RNA titers were significantly diminishedat endtreatment compared to pretreatment. Unfortunately, we did not observe a case with no titer of HCV-RNA. Alanineaminotransferase values and other parameters were not affected by GGA treatment.Conclusion. GGA has anti-HCV activities in chronic hepatitis C-infected patients. In the future, it will be necessary to examinethe clinical effectiveness of the combination of treatment with both GGA and interferon in HCV patients., identifier:Acta Medica Nagasakiensia, 57(1), pp.1-4; 2012

Published
2020

21. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.

Author

Goto, Takashi, Ishikawa, Hiroki, Matsumoto, Kojiro, Nishimura, Daisuke, Kusaba, Mariko, Taura, Naota, Shibata, Hidetaka, Miyaaki, Hisamitsu, Ichikawa, Tatsuki, Hamasaki, Keisuke, Nakao, Kazuhiko, Maeshima, Yohei, Eguchi, Katsumi, Goto, Takashi, Ishikawa, Hiroki, Matsumoto, Kojiro, Nishimura, Daisuke, Kusaba, Mariko, Taura, Naota, Shibata, Hidetaka, Miyaaki, Hisamitsu, Ichikawa, Tatsuki, Hamasaki, Keisuke, Nakao, Kazuhiko, Maeshima, Yohei, and Eguchi, Katsumi

Abstract

Since hepatocellular carcinoma (HCC) is a hypervascular cancer, anti-angiogenic therapy is a promising approach to treat HCC. In the present study, we investigated the antiangiogenic and antitumor effects of tum-1, a fragment of tumstatin, gene transduction into HCC in vitro and in vivo. Tum-1 gene was cloned into a pSecTag2B mammalian expression vehicle to construct pSecTag2B-tum-1. pSecTag2B-tum-1 or vehicle were transfected into human HCC cells, PLC/PRF/5 cells stably and Huh-7 cells tran-siently. pSecTag2B-tum-1 transfection slightly repressed the proliferation of both PLC/PRF/5 and Huh-7 cells in vitro. Addition of conditioned media (CM) from tum-1 expressing PLC/PRF/5 cells significantly inhibited the spontaneous and vascular endothelial growth factor (VEGF)-induced proliferation and migration of human umbilical vein endothelial cells (HUVEC) in vitro with diminishing the VEGF-induced phosphorylation of both Akt and extracellular signal-regulated kinase (ERK) that are known to mediate VEGF-induced proliferation and migration of endothelial cells. In in vivo experiments, intratumoral injection of pSecTag2B-tum-1 significantly repressed the growth of pre-established Huh-7 tumors in athymic mouse models accompanying the decreased density of CD34 positive vessels in tumors. In conclusion, our results suggest that antiangiogenic gene therapy using tum-1 gene may be an efficient strategy for the treatment of HCC., identifier:International Journal of Oncology, 33(1), pp.33-40; 2008

Published
2020

22. Abstracts of selected papers presented at the 78th general meeting of the Japanese Society of Gastroenterology

Author

Kusano, Motoyasu, Sekiguchi, Toshikazu, Hanyu, Nobuyoshi, Aoki, Teruaki, Matsushima, Yasuhiro, Okamoto, Eizo, Takeda, Yasuo, Takeda, Ryoyu, Miyachi, Masahiko, Nimura, Yuji, Arai, Taidoh, Masuda, Jun, Tanaka, Masao, Ogawa, Yoshiaki, Ura, Kazuhide, Matsumoto, Teiji, Taniyama, K., Kurosawa, Susumu, Owyang, Chung, Baba, Hiroshi, Fujimura, Masaki, Hamada, Eiji, Shimada, Tadahito, Kabemura, Teppei, Chijiiwa, Yoshiharu, Sato, T., Koito, K., Matsuda, Hiroko, Kawasaki, Tsunehisa, Obara, Katsutoshi, Kasukawa, Reiji, Miyoshi, Hirofumi, Matsumoto, Akio, Yamamoto, Manabu, Ohmasa, Ryouji, Kokubu, Shigehiro, Shibata, Hisao, Tajiri, Takashi, Onda, Masahiko, Hashizume, Makoto, Sugimachi, Keizo, Kobayashi, Kenji, Shiozaki, Hitoshi, Fujisaki, Junko, Shimoda, Tadakazu, Hase, Satoshi, Tsukamoto, Yoshihisa, Atsumi, M., Konishi, H., Nakajo, Shinobu, Fujiyama, Yoshihide, Taruishi, Masaki, Ayabe, Tokiyoshi, Morise, Kimitomo, Yamaguchi, Takeo, Makiyama, Kazuya, Itsuno, Minoru, Matsui, T., Okabe, N., Okabe, Nobuo, Matsui, Toshiyuki, Sakatani, Arata, Koizumi, Koichi, Imai, Yutaka, Sugino, Yoshinori, Masaki, Tadahiko, Sawada, Toshio, Nishigami, Takashi, Satomi, Masamichi, Hatada, Yasumasa, Saito, Hiroshi, Kobayshi, Kiyonori, Katsumata, Tomoe, Sugimoto, Kenji, Itabashi, Tsukasa, Kitagawa, Motoji, Hayakawa, Tetsuo, Okazaki, Kazuichi, Yamamoto, Yasuro, Funakoshi, Akihiro, Miyasaka, Kyoko, Soejima, Kazuhiko, Kanda, Mikio, Sugiyama, Masanori, Kuroda, Akira, Inoue, Hisayuki, Bamba, Tadao, Hamanaka, Y., Suzuki, T., Suzuki, Mamoru, Hanyu, Fujio, Tamura, Katsuhiro, Nakase, Akira, Noguchi, M., Hiwatashi, N., Murata, Yuhji, Suzuki, Kazuo, Ohtani, Haruo, Watanabe, Yoshihisa, Zeniya, Mikio, Aizawa, Yoshio, Masumoto, T., Onji, M., Hamasaki, Keisuke, Nakata, Keisuke, Fukui, Hiroshi, Tsujii, Tadasu, Yamashiki, Masayoshi, Nishimura, Akira, Tsutsui, Hiroko, Mizoguchi, Yasuhiro, Kimura, Fumio, Miyazaki, Masaru, Kiyota, Keisuke, Inokuchi, Hideto, Yamamoto, Yoshihiro, Oka, Hiroshi, Horikoshi, Tsutomu, Sekiguchi, Toshikazu, Takayasu, H., Shirai, T., Hongo, Michio, Okuno, Yo, Okano, H., Aoyama, N., Ohsuki, Masao, Maeda, Kenji, Haruma, Ken, Sumii, Koji, Nakai, Yoshihide, Fukunaga, Mikihiko, Kaneko, Hiroshi, Morise, Kimitomo, Okumura, Toshikatsu, Uehara, Akira, Fukuda, Yoshihiro, Satomi, Masamichi, Joh, Takashi, Itoh, Makoto, Kitagawa, Yuko, Kitajima, Masaki, Iwao, Tadashi, Toyonaga, Atsushi, Nakamura, Masahiko, Oda, Masaya, Kawamura, Yukimitsu, Dohden, Kenji, Kamiyama, Yasuhiko, Matsuno, Seiki, Hirano, Morihisa, Otsuka, Sachio, Ito, Masahiro, Sekine, Ichiro, Ogihara, Tatsuo, Sato, Nobuhiro, Uehara, Akira, Namiki, Masayoshi, Sugiura, Nobuyuki, Ebara, Masaaki, Matsuo, Naoki, Uchida, Hideo, Okada, Shuichi, Okazaki, Nobuo, Tsujii, Hirohiko, Ohsuga, Toshiaki, Abe, M., Nagata, Y., Yamasaki, Susumu, Kosuge, Tomoo, Kitamoto, Mikiya, Nakanishi, Toshio, Ichikawa, Yuzo, Mizoguchi, Yasuhiro, Ohtake, Yoshio, Hirasawa, Hiroyuki, Sugihara, Junichi, Muto, Yasutoshi, Yasunaga, Mitsuru, Okita, Kiwamu, Ukida, Minoru, Tsuji, Takao, Isai, Hideya, Uchino, Junichi, Suzuki, Katsuhiko, Komatsu, Kanji, Ohtomo, Yumiko, Idezuki, Yasuo, Sakuramachi, Shunji, Kimura, Taizo, Kitano, Seigo, Sugimachi, Keizo, Moriyama, Masaaki, Yazaki, Yasuyuki, and Saito, Takashige

Published
1993
Full Text
View/download PDF

23. 5th Japanese Association of Hepato-Biliary-Pancreatic Surgery: October 14–15, 1993, Arcadia Ichigaya, Tokyo, Japan President: Fujio Hanyu

Author

Miyazaki, Kohji, Tsutsumi, Nobuo, Kitahara, Kenji, Mori, Michito, Sasatomi, Eizaburo, Hirohashi, Yoshimi, Mashima, Hideaki, Hisatsugu, Takeharu, Sugiura, Yoshiaki, Kamiya, Takashi, Hiroyasu, Shungo, Takatsu, Izuru, Yoshizumi, Yutaira, Shima, Shingo, Tanaka, Susumu, Tashiro, Seiki, Tsuji, Tatsuya, Oda, Tsutomu, Kanemitsu, Keiichiro, Kamimoto, Yukio, Hiraoka, Takehisa, Miyauchi, Yoshimasa, Tanaka, Junji, Arii, Shigeki, Fujita, Ken Ichi, Imamura, Masayuki, Kanai, Michio, Nimura, Yuji, Hayakawa, Naokazu, Kamiya, Junichi, Kondoh, Satoshi, Nagino, Masato, Miyachi, Masahiko, Tatsuya, Yoshikawa, Hanyu, Fujio, Nakamura, Mitsuji, Araida, Tatsuo, Azuma, Tsukasa, Mutou, Hiroaki, Moriyama, Toru, Kogure, Michio, Asano, Takehide, Enomoto, Kazuo, Yamamoto, Hiroshi, Kobayashi, Susumu, Nagashima, Tohru, Uematsu, Takeshi, Amano, Hodaka, Nakagouri, Toshio, Kainuma, Osamu, Tokoro, Yoshiharu, Matsui, Yoshifumi, Jinguh, Kazuhiko, Miyauchi, Hideaki, Maruyama, Michihiro, Iwashita, Chikara, Isono, Kaichi, Mimura, Hisashi, Hamazaki, Keisuke, Tsuge, Hiromu, Kawada, Noriyuki, Yamamoto, Junji, Yamasaki, Susumu, Kosuge, Tomoo, Shimada, Kazuaki, Takayama, Tadatoshi, Ozaki, Hideo, Tomioka, Tsutomu, Ikematsu, Yoshito, Matsukawa, Shunichi, Tajima, Yoshitsugu, Sasaki, Makoto, Segawa, Tohru, Tsunoda, Tsukasa, Kanematsu, Takashi, Yamanaka, Naoki, Okamoto, Eizo, Oriyama, Tsuyoshi, Andoh, Tatsuya, Furukawa, Kazutaka, Todoroki, Takeshi, Kawamoto, Toru, Orii, Kazuo, Fukao, Katashi, Saida, Yukihisa, Yamamoto, Masakazu, Takasaki, Ken, Ootsubo, Takehito, Katsuragawa, Hideo, Maruyama, Chifumi, Yoshikawa, Tatsuya, Saisho, Hiromitsu, Sumita, Masatoshi, Okada, Shuichi, Tsuyuguchi, Toshio, Tsuchiya, Yukihiro, Ohto, Masao, Hirohashi, Kazuhiro, Kinoshita, Hiroaki, Kubo, Shoji, Tanaka, Hiromu, Tsukamoto, Tadashi, Hamba, Hiroyuki, Shuto, Taichi, Takemura, Shigekazu, Ikeda, Kazuo, Okuda, Toyokazu, Nakamura, Satoshi, Nishiyama, Raisuke, Konno, Hiroyuki, Baba, Shozo, Ogura, Yoshifumi, Tabata, Masanti, Takahashi, Koji, Ido, Masayoshi, Isaji, Shuji, Yokoi, Hajime, Noguchi, Takashi, Kawarada, Yoshifumi, Mizumoto, Ryuji, Nakao, Akimasa, Takagi, Hiroshi, Nagakawa, Takukazu, Ueno, Keiichi, Ohta, Tetsuo, Kayahara, Masato, Yoshimitsu, Yutaka, Suzaki, Yuhkei, Tukioka, Yuhji, Miyazaki, Itsuo, Imaizumi, T., Hanyu, F., Suzuki, M., Nakasako, T., Harada, N., Arai, T., Hirose, T., Fukuda, A., Munakata, S., Ozawa, F., Nagai, Hideo, Kondo, Yasuo, Yasuda, Toshihiko, Ishibashi, Toshimitsu, Kasahara, Kogoro, Kanazawa, Kyotaro, Ishikawa, Yasuro, Konagaya, Ichiro, Naoe, Teturo, Amano, Hitoshi, Kasugai, Hisashi, Sakai, Shigeru, Kano, Nobuyasu, Yamakawa, Tatsuo, Tagaya, Nobumi, Kaneko, Mitsuo, Takagi, Kazutoshi, Itoh, Makoto, Kogure, Hiroaki, Tajima, Yoshio, Yamamoto, Hideo, Kondo, Satoshi, Hamaguchi, Katsura, Komatu, Shunichiro, Yoshida, Masayuki, Kimura, Taizo, Tsugawa, Kouichiro, Konishi, Kohji, Takada, Osamu, Nagata, Takuya, Futagami, Fumio, Yamamoto, Seiichi, Maeda, Kiichi, Yabushita, Kazuhisa, Kuroda, Yoshitaka, Tsuji, Masahiko, Takada, Johji, Saji, Yutaka, Arisato, Hitoshi, Kurauchi, Nobuaki, Kazui, Keizo, Yamaga, Shoji, Nakayama, Masato, Uchino, Junichi, Takahasi, Shin, Tsuzuki, Toshiharu, Nakano, Akira, Sekido, Hitoshi, Endo, Itaru, Mochizuki, Yasuhisa, Fukushima, Tadao, Fukasawa, Shingo, Yoda, Kohei, Ogura, Kensuke, Shimada, Hiroshi, Tsukada, Kazuhiro, Hatakeyama, Katsuyosi, Kurosaki, Isao, Uchida, Katsuyuki, Shirai, Yosio, Muto, Terukazu, Takano, Seigo, Seki, Noriyoshi, Ooishi, Toshihiko, Watanabe, Yoshihiro, Higaki, Tokio, Moriguchi, Masanori, Itou, Yutaka, Tanaka, Takashi, Sasaki, Ryoko, Kanno, Senji, Hayakawa, Yoshiro, Murakami, Masahiko, Kawamura, Hidenobu, Shimada, Yutaka, Suto, Takayuki, Tamasawa, Yoshiyuki, Saito, Kazuyoshi, Sasatomi, Eizaburoh, Okuno, Toshitaka, Nakayama, Shinji, Fukuhara, Toshiyuki, Hashimoto, Takashi, Takamine, Yoshikazu, Konishi, Yutaka, Tani, Tomohiko, Kajiwara, Tatehiro, Okada, Setuo, Hashimoto, Tetuaki, Wakabayashi, Hisao, Maeba, Takashi, Tanaka, Satoshi, Oishi, Toshinori, Kumazawa, Ken ichi, Kubota, Koichi, Hosokawa, Toshihiko, Yoshizawa, Shuichi, Asami, Yoshiaki, Shiozawa, Shun ichi, Otani, Yoichi, Haga, Shunsuke, Kajiwara, Tetsuro, Harada, Akio, Kurokawa, Tsuyoshi, Maruyama, Hirotaka, Kobayashi, Hiroyuki, Nonami, Toshiaki, Katsuramaki, Tadashi, Kimura, Masami, Takasaka, Hajime, Mukaiya, Mitsuhiro, Yamashiro, Kazuhiro, Mikami, Toshihiko, Kimura, Hiromichi, Hirata, Koichi, Mimura, Takuji, Koguchi, Keiji, Hamazaki, Keisuke, Mori, Masanobu, Edahiro, Tooru, Orita, Kunzo, Koyama, Hiroshi, Taniguchi, Hiroki, Oguro, Atsushi, Takeuchi, Kazumi, Miyata, Keigo, Tanaka, Hiroki, Takahashi, Toshio, Ishii, Takahiro, Kim, Yang Il, Aramaki, Masanori, Nakashima, Kimihiro, Yochida, Takanori, Kobayashi, Michio, Ohura, Shinsuke, Beppu, Tomoe, Ohashi, Kaoru, Watanabe, Isamu, Kojima, Kuniaki, Fukasawa, Masaki, Futagawa, Shunji, Watanabe, Xoshihiro, Takahashi, Tomohide, Shimazu, Motohide, Aoki, Haruo, Naomoto, Yoshio, Kawata, Noriyuki, Hamazaki, Keisuke, Mori, Seiji, Misawa, Atushi, Kawamura, Eisuke, Tanaka, Tsuneo, Tomoda, Fumihito, Ichikawa, Nobutaka, Tanaka, Wataru, Yasui, Chiaki, Kuroda, Youichi, Mori, Naoharu, Yamaguchi, Akihiro, Isogai, Masatoshi, Hori, Akihiro, Maeda, Atsuyuki, Kawai, Masami, Takano, Manabu, Yamaguchi, Ryuzo, Kubota, Tomoyuki, Yamada, Tatsuharu, Yokoyama, Yukihiro, Matsunaga, Kazuya, Takeuchi, Yuuki, Ogawa, Tomoko, Tabata, Masami, Noguchi, Takashi, Nagashima, Ikuo, Sumita, Toshiyuki, Sodeyama, Motohide, Saito, Hideaki, Kawano, Nobuhiro, Muto, Tetsuichiro, Yoshida, Muneki, Takahashi, Tsuyoshi, Furuta, Kazunori, Izumika, Hisanao, Omiya, Harumi, Hiki, Yoshiki, Kakita, Akira, Hata, Tsunetake, Une, Yoshie, Nakajima, Yasuaki, Sato, Naoki, Matsushita, Michiaki, Kamiyama, Toshiya, Shimamura, Tsuyoshi, Nakagawa, Takahiro, Misawa, Kazuhito, Akiyama, Takayoshi, Seto, Keitarou, Saitou, Hitoshi, Kiriyama, Masato, Tomita, Fujio, Kosaka, Takeo, Kita, Ichirou, Takashima, Shigeki, Misuta, Koichiro, Endo, Ataru, Shimozawa, Eiji, Kato, Hiroyuki, Ooura, Takehiko, Nohira, Kunihiko, Shintomi, Yoshinao, Yuzawa, Kenji, Otsuka, Masaaki, Nozue, Mutsumi, Kato, Shuji, Kuramoto, Kenmei, Kasano, Yasuo, Tanimura, Hiroshi, Taniguchi, Katsutoshi, Hayashido, Motonori, Takifuji, Katsunari, Ozaki, Takashi, Sakamoto, Tomosaburo, Miyata, Masahiko, Izukura, Masaaki, Tanaka, Yasuhiro, Mizutani, Shin, Tominaga, Harumi, Yosidome, Katsuhide, Matsuda, Hikaru, Shimahara, Yasuyuki, Ichimiya, Masato, Jin, Maeng Bong, Kinoshita, Koichi, Mori, Keiichiro, Yamaoka, Yoshio, Kobayashi, Nobuaki, Ozawa, Kazue, Kawabe, Norihiko, Matsumoto, Sumio, Matsumoto, Kiyoshi, Yoshida, Yoshihiko, Sano, Makoto, Mori, Kenji, Tsukada, Norio, Kitagawa, Hiroaki, Mizuno, Yuhou, Kimura, Tadahiro, Suzuki, Hiroichirou, Banno, Tetsuya, Hiraoka, Hiroshi, Monta, Nobuyoshi, Noshima, Shinji, Shinagawa, Hidetaka, Esato, Kensuke, Miki, Tosio, Ito, Yutaka, Moriguti, Masanori, Takahasi, Tomohide, Kusano, Toshiomi, Honma, Kaneatsu, Tokumine, Fumio, Tamaki, Satoshi, Okushima, Norihiko, Muto, Yoshihiro, Furukawa, Masato, Kin, Yukon, Uesaka, Katsuhiko, Sugimoto, Yoshihiro, Tabuse, Katsuyoshi, Shimotsuma, Nakahiro, Yamamoto, Seiki, Sakaguchi, Masahiro, Mori, Kazunari, Oka, Masami, Asano, Satoshi, Kinoshita, Hiroyuki, Nagahama, Miho, Arii, Kazuo, Minami, Koji, Mizusaki, Kaoru, Takahasi, Tsuneo, Yanagisawa, Satoru, Naruse, Masaru, Akita, Haruyuki, Touyama, Youichi, Cho, Takemasa, Tanaka, Jun, Aoki, Teruaki, Yamauchi, Junichiro, Takeda, Kazunori, Shibuya, Kazuhiko, Sunamura, Makoto, Arai, Kousuke, Kawaguchi, Shinya, Kobari, Masao, Matsuno, Seiki, Shiobara, Masayuki, Miyazaki, Masaru, Itoh, Hiroshi, Kaiho, Takashi, Andoh, Katsuhiko, Anbiru, Satoshi, Hayashi, Shinichi, Gohchi, Eiji, Nagai, Motoki, Takanishi, Kijurou, Togawa, Akira, Ohtsuka, Masayuki, Sasada, Kazuhiro, Shimizu, Yoshiaki, Yoshioka, Shigeru, Yoshidome, Hiroyuki, Katoh, Atsushi, Nakamura, Syunta, Nakajima, Nobuyuki, Sutoh, Takayuki, Sasaki, Kohsuke, Sasaki, Ryoukou, Takayama, Wataru, Watanabe, Kazuo, Asahara, Toshimasa, Dohi, Kiyohiko, Nakahara, Hideki, Okamoto, Yusou, Ochi, Makoto, Katayama, Kouji, Itamoto, Toshiyuki, Nomura, Shinnya, Marubayashi, Seiji, Ono, Eiji, Yahata, Hiroshi, Fukuda, Yasuhiko, Ooshiro, Hisashi, Sasaki, Makoto, Tsunoda, Tsukasa, Matsunaga, Naofumi, Maki, Atsuhiko, Takabayashi, Arimichi, Kurumi, Yoshimasa, Kishida, Akihiro, Haeuchi, Kazuo, Yamamoto, Takumi, Watanabe, Hidejiro, Hase, Takanobu, Kodama, Masashi, Marugami, Yoshihisa, Matubara, Toshiki, Futawatari, Hisatomo, Nakamura, Kohji, Imazu, Hiroki, Arai, Kazufumi, Mori, Kikuo, Suganima, Masashi, Morishita, Hirosi, Sasayama, Yoshinori, Tsuda, Singo, Maruta, Yuuji, Muraoka, Masaaki, Ochiai, Masahiro, Funabiki, Takahiko, Siobara, Masayuki, Kondoh, Yoichiro, Hayashi, Jitsuo, Tanigawa, Kanji, Noguchi, Takashi, Okamoto, Yuzo, Nomura, Shinya, Okamoto, Tomoyoshi, Inagaki, Yoshinori, Takahashi, Tsuneo, Shinagawa, Hidenori, Morita, Nobuyoshi, Kato, Tomohiro, Hamasaki, Keisuke, Tuge, Hiroshi, Isozaki, Hiroshi, Okajima, Kunio, Ishibashi, Takashi, Morita, Shinsho, Hara, Hitoshi, Tanimura, Masakazu, Tezuka, Kiyotaka, Akimoto, Hiroshi, Niki, Masami, Okuda, Junji, Kogure, Kimitaka, Ishizaki, Masatoshi, Nemoto, Masaaki, Muratani, Mitsugu, Kosugi, Mitsuyo, Kiyohara, Kaoru, Yano, Takashi, Iida, Toshio, Kida, Hideya, Akasaka, Yoshikazu, Amano, Kazuya, Fujimori, Kenji, Ishihara, Akinori, Kakizaki, Kenji, Yamauchi, Hidemi, Uno, Satomi, Osada, Shinji, Kanno, Akihiro, Katou, Motohisa, Sugiyama, Yasuyuki, Miya, Kiichi, Saji, Shigetoyo, Horimi, Tadashi, Ishikawa, Tadanori, Takasaki, Motohiro, Morita, Sojiro, Nakamura, Tohru, Suganuma, Yasushi, Aoki, Hideki, Hatsuse, Kazuo, Terahata, Shintaro, Irie, Toshiyuki, Murayama, Michinori, Aihara, Tsukasa, Tamakuma, Shoetsu, Uyama, Ichiro, Iida, Shuhei, Ogiwara, Hiroyuki, Kikuchi, Kaichiro, Takahara, Tetsuya, Katou, Yutaro, Kwon, A Hon, Uetsuji, Shoji, Yamada, Osamu, Inoue, Tomohisa, Kurimoto, Shuji, Komada, Hisanao, Kamiyama, Yasuo, Boku, Tsunehide, Kohno, Hitoshi, Nagasue, Naofumi, Hayashi, Takafumi, Yamanoi, Akira, Uchida, Masaaki, Takemoto, Yoshinari, Makino, Yoshinari, Ono, Takashi, Hayashi, Junko, Nakamura, Teruhisa, Kikuchi, Toshiyuki, Okazuini, Shin ichi, Iwasaki, Koutarou, Makino, Harufumi, Niimoto, Syuichi, Hirose, Kazurou, Seki, Hiroaki, Isobe, Yoshiaki, Yamaguchi, Akio, Nakagawara, Gizou, Idota, Nozomi, Shono, Satoshi, Sakai, Yoshihiro, Kakihara, Minoru, Suzuki, Hideaki, Konishi, Masaru, Ryu, Munemasa, Shimamura, Yoshiyuki, Kinoshita, Taira, Kawano, Noriaki, Tanizaki, Hiroshi, Arai, Yoshihide, Ohashi, Kazuo, Nakajima, Yoshiyuki, Masahiro, Tsutsumi, Kanehiro, Hiromiti, Fukuoka, Toshiyuki, Naito, Azusa, Konishi, Yoichi, Nakano, Hiroshige, Kawamura, Hiroshi, Ishiyama, Shuichi, Seo, Nobuo, Fuse, Akira, Kuzu, Hiroshi, Sutoh, Koichi, Tsukamoto, Masaru, Takamori, Shigeru, Fukazawa, Masaki, Okuyama, Kouichi, Watanabe, Shin, Takamatsu, Susumu, Goseki, Narihide, Teramoto, Kenichi, Katoh, Shouichi, Hara, Yuzuru, Dobashi, Yasuyuki, Endoh, Mitsuo, Ohta, Kyosuke, Kanamaru, Taich, Usami, Makoto, Sakata, Kazuya, Haji, Seiji, Kotani, Jorge, Iso, Atsunori, Kasahara, Hiroshi, Ku, Eisei, Yamamoto, Masahiro, Saitoh, Yoichi, Hirano, Satoshi, Katoh, Hiroyuki, Okajima, Susumu, Miyasaka, Yuji, Nishibe, Toshiya, Narita, Yoshiaki, Doke, Mitsuru, Okushiba, Shunichi, Koyama, Hiroshi, Mitsui, Takeshi, Miura, Shoji, Munemoto, Yoshinori, Asada, Yasuyuki, Kasahara, Yoshio, Nagasato, Atsushi, Iida, Yoshiro, Saito, Hideo, Fujisawa, Masakiyo, Hazama, Shoichi, Oka, Masaaki, Hiwaki, Kazuhisa, Hiraki, Sakurao, Tangoku, Akira, Shimoda, Kouji, Suzuki, Michinari, Iizuka, Norio, Wadamori, Kenji, Suzuki, Takashi, Kimura, Wataru, Kanazawa, Gyotaro, Oka, Masatni, Iwagaki, T., Takada, T., Yasuda, H., Uchiyama, K., Hasegawa, H., Ushitani, H., Yamakawa, Y., Fujii, Shoichi, Ooki, Shigeo, Sugita, Akira, Togo, Shinji, Imai, Shinsuke, Fukazawa, Shingo, Ishihara, Shinichi, Masui, Hidenobu, Yamamoto, Masayoshi, Yoda, Kouhei, Yanaga, Katsuhiko, Shimada, Mitsuo, Higashi, Hidefumi, Taketomi, Akinobu, Matsumata, Takashi, Sugimachi, Keizo, Nishida, Minekatsu, Yagyu, Takashi, Nakashima, Kazutaka, Shimizu, Ryoichi, Uchiyama, Tetsushi, Miyazaki, Masaru, Ambiru, Satoshi, Takanishi, Kijuro, Togawa, Akira, Yoshitome, Hiroyuki, Nakamura, Shunta, Sano, Yoshiaki, Suwa, Toshikazu, Kondo, Satosi, Koide, Shinji, Torimoto, Katsuji, Denno, Rhyuichi, and Hamazaki, Keisuke

Published
1993
Full Text
View/download PDF

27. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma

Author

Ohkubo, Kazuaki, Kato, Yuji, Ichikawa, Tatsuki, Kajiya, Yuji, Takeda, Yoshio, Higashi, Shinnichirou, Hamasaki, Keisuke, Nakao, Kazuhiko, Nakata, Keisuke, and Eguchi, Katsumi

Subjects
Medical research -- Analysis, Cancer -- Research, Hepatitis B virus -- Causes of, Liver cancer -- Research, Viremia -- Measurement, HIV patients -- Care and treatment, Health, Nagasaki University -- Research
Published
2002

32. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions

Author

Minayoshi, Yuki, Maeda, Hitoshi, Yanagisawa, Hiroki, Hamasaki, Keisuke, Mizuta, Yuki, Nishida, Kento, Kinoshita, Ryo, Enoki, Yuki, Imafuku, Tadasi, Chuang, Victor Tuan Giam, Koga, Tomoaki, Fujiwara, Yukio, Takeya, Motohiro, Sonoda, Kayoko, Wakayama, Tomohiko, Taguchi, Kazuaki, Ishima, Yu, Ishida, Tatsuhiro, Iwakiri, Yasuko, Tanaka, Motohiko, Sasaki, Yutaka, Watanabe, Hiroshi, Otagiri, Masaki, and Maruyama, Toru

Abstract

Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on the preparation of a Kupffer cell targeting type-I interferon, an albumin-IFNα2b fusion protein that contains highly mannosylated N-linked oligosaccharide chains, Man-HSA(D494N)-IFNα2b, attached by combining albumin fusion technology and site-directed mutagenesis. The presence of this unique oligosaccharide permits the protein to be efficiently, rapidly and preferentially distributed to Kupffer cells. Likewise IFNα2b, Man-HSA(D494N)-IFNα2b caused a significant induction in the mRNA levels of IL-10, IL-1Ra, PD-L1 in RAW264.7 cells and mouse isolated Kupffer cells, and these inductions were largely inhibited by blocking the interferon receptor. These data indicate that Man-HSA(D494N)-IFNα2b retained the biological activities of type-I interferon. Man-HSA(D494N)-IFNα2b significantly inhibited liver injury in Concanavalin A (Con-A)-induced hepatitis model mice, and consequently improved their survival rate. Moreover, the post-administration of Man-HSA(D494N)-IFNα2b at 2 h after the Con-A challenge also exerted hepato-protective effects. In conclusion, this proof-of-concept study demonstrates the therapeutic effectiveness and utility of Kupffer cell targeting type-I interferon against hepatitis via its anti-inflammatory and immunomodulatory actions.

Published
2019
Full Text
View/download PDF

41. Treatment of hepatocellular carcinoma with transcatheter arterial embolization: analysis of prognostic factors

Author

Taniguchi, Kenji, Nakata, Keisuke, Kato, Yuji, Sato, Yoshiaki, Hamasaki, Keisuke, Tsuruta, Shohtaro, and Nagataki, Shigenobu

Subjects
Liver cancer -- Care and treatment, Arterial catheterization -- Usage, Health
Abstract

Background. Transcatheter arterial embolization (TAE) is a useful treatment modality for hepatocellular carcinoma (HCC). To study the prognostic factors, survival time of patients with HCC after TAE was analyzed retrospectively using clinical manifestations of coexisting liver cirrhosis and clinical features of HCC. Methods. Eighty-seven patients with HCC were treated with TAE between 1984 and 1991 and observed at Nagasaki University Hospital. All the patients also had liver cirrhosis. Results. The survival time of the 87 patients after TAE ranged from 2 months to 8.1 years (mean [plus or minus] standard deviation, 2.7 [plus or minus] 0.3 years). Survival curves after TAE did not differ between men and women (P > 0.5) or between hepatitis B and C viral infection (P > 0.8), but they depended on clinical stages of coexisting liver cirrhosis (P < 0.01). The cumulative survival after TAE was significantly longer in patients with uninodular tumors than in patients with multinodular tumors (P < 0.0001) (3-year survival, 53.3% vs. 13.3%; 5-year survival, 32.2% vs. 3.3%, respectively). In contrast, patients' survival time was not associated with the size of the tumor detected at the time of treatment with TAE (P > 0.1). Conclusions. Treatment of HCC with TAE is well indicated regardless of tumor size for patients with nonadvanced liver cirrhosis and uninodular tumors. Alternatively, treatment of HCC with TAE alone is still insufficient in patients with multinodular tumors. Other treatment modalities in combination with TAE should be considered to achieve a more favorable prognosis of these patients. Cancer 1994; 73:1341-5.

Published
1994

44. Anti-hepatitis C virus activity of geranylgeranylacetone treatment in hepatitis C-infected patients

Author

Yamaguchi, Tohei, Ichikawa, Tatsuki, Takeshita, Shigeyuki, Taura, Naota, Miyaaki, Hisamitsu, Muraoka, Toru, Shibata, Hidetaka, Honda, Takuya, Hamasaki, Keisuke, Kato, Yuji, Takeshima, Fuminao, and Nakao, Kazuhiko

Subjects
Hepatitis C virus, geranylgeranylacetone, chronic hepatitis C
Abstract

Background. Geranylgeranylacetone (GGA), which is an isoprenoid compound, has been used orally as an antiulcer drug in Japan. GGA induces antiviral gene expression by stimulating the formation of interferon-stimulated gene factor 3 in human hepatoma cells. This study verified the anti-hepatitis C virus (HCV) activity of GGA in chronic hepatitis C-infected patients. Methods. The present prospective study included 20 consecutive anti-HCV antibody-positive, HCV-genotype 1b, and chronic gastritis patients who visited Nagasaki University Hospital between January 1999 and December 1999. GGA (150 mg per day, which is the dose generally used for chronic gastritis) was taken orally for four weeks. We evaluated HCV-RNA titers and other clinical parameters at pretreatment, posttreatment, and at the endpoint of the study. Pretreatment was the beginning point of GGA treatment. Posttreatment was the termination point of GGA treatment. The endpoint was the point four weeks after the posttreatment point. Results. All patients completed four weeks of GGA treatment and four weeks of observation. HCV-RNA titers at postpoint were not significantly diminished compared to those at pretreatment. However, HCV-RNA titers were significantly diminished at endtreatment compared to pretreatment. Unfortunately, we did not observe a case with no titer of HCV-RNA. Alanine aminotransferase values and other parameters were not affected by GGA treatment. Conclusion. GGA has anti-HCV activities in chronic hepatitis C-infected patients. In the future, it will be necessary to examine the clinical effectiveness of the combination of treatment with both GGA and interferon in HCV patients., Acta Medica Nagasakiensia, 57(1), pp.1-4; 2012

Published
2012

45. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions

Author

Minayoshi, Yuki, primary, Maeda, Hitoshi, additional, Yanagisawa, Hiroki, additional, Hamasaki, Keisuke, additional, Mizuta, Yuki, additional, Nishida, Kento, additional, Kinoshita, Ryo, additional, Enoki, Yuki, additional, Imafuku, Tadasi, additional, Chuang, Victor Tuan Giam, additional, Koga, Tomoaki, additional, Fujiwara, Yukio, additional, Takeya, Motohiro, additional, Sonoda, Kayoko, additional, Wakayama, Tomohiko, additional, Taguchi, Kazuaki, additional, Ishima, Yu, additional, Ishida, Tatsuhiro, additional, Iwakiri, Yasuko, additional, Tanaka, Motohiko, additional, Sasaki, Yutaka, additional, Watanabe, Hiroshi, additional, Otagiri, Masaki, additional, and Maruyama, Toru, additional

Published
2018
Full Text
View/download PDF

46. The Japanese Society of Internal Medicine

Author

Fujikawa, Keita, Ohata, Kazuyuki, Honda, Takuya, Miyazoe, Seiji, Ichikawa, Tatsuki, Ishikawa, Hiroki, Hamasaki, Keisuke, Nakao, Kazuhiko, Toriyama, Kan, and Eguchi, Katsumi

Subjects
nutritional and metabolic diseases, hepatic fibrosis, weight reduction, nonalcoholic steatohepatitis
Abstract

A 65-year-old woman was admitted to our hospital for an investigation of liver dysfunction. She had mild obesity with hyperlipidemia, but no history of alcohol abuse. Other known causes of liver dysfunction, such as viruses, autoimmunity and drug effects, were excluded. The liver histology was consistent with nonalcoholic steatohepatitis (NASH). After diagnosis of NASH, the patient started diet and exercise therapy and, in parallel with weight reduction, her liver function improved. One year after the therapy, a liver biopsy showed that steatosis, necroinflammation and even fibrosis were improved. Hence, here we report a case of NASH in which weight reduction was effective in improving both biochemical and histological findings.

Published
2004

47. Attenuation of Responsiveness to Interferon-α Treatment by Preceded Overactivation of Interferon-mediated Pathway in Patients Chronically Infected by Hepatitis C Virus

Author

Nakata, Keisuke, Nakao, Kazuhiko, Morikawa, Takashi, Inokuchi, Kaoru, Hamasaki, Keisuke, Tsuruta, Shotaro, Kato, Yuji, Yatsuhashi, Hiroshi, Kusumoto, Yukio, Ishii, Nobuko, and Eguchi, Katsumi

Subjects
hepatitis C virus, inter feron regulatory factor-1, interferon regulatory factor-2, interferon treatment, chronic hepatitis C
Abstract

The Interferon (IFN) receptor-mediated signal transduction pathways involve the two novel DNA-binding factors, interferon regulatory factor-1 (IRF-1) and IRF-2. Both recognize the same DNA sequence, in which the expression ratio of IRF-1 to IRF-2 is relevant to induction of IFN-inducible genes, because IRF-1 acts as a transcriptional activator and IRF-2 as a counterpart. In the present study, 54 patients with chronic hepatitis C and the age-and sex-matched 7 subjects with fatty liver as a control were subjected to analysis of the expression ratio of IRF-1 to IRF-2 mRNA in the liver tissue obtained at the time of livert biopsy by reverse transcription-polymerase chain reaction in combination with a restriction fragment length polymorphism assay. The expression ratio of IRF-1 to IRF-2 mRNA in the liver tissue in patients chronically infected by hepatitis C virus (HCV) was significantly higher than that in control, although the values did not correlate with the serum levels of HCV-RNA. Of 54 patients, 28 received IFN treatment, resulting in complete response in 8 patients. With respect to responsiveness to IFN treatment, patients who had complete response had the relatively lower ratios of IRF-1 to IRF-2 mRNA in the liver tissue, compared with those who did not. These results indicate that the IFN-mediated pathway is spontaneously activated in patients with chronic hepatitis C, and that its preceded overactivation counteracts on the efficacy of IFN treatment in these patients., Acta medica Nagasakiensia. 2000, 45(3-4), p.15-19

Published
2000

48. Proceedings of the 25th annual meeting From October 13–15, 1983—Yamaguchi, Japan

Author

Takasu, Sachio, Takizawa, Thouichiro, Koike, Morio, Tatsuta, Masaharu, Okuda, Shigeru, Okuda, Junichi, Ida, Kazunori, Yamada, Naoyuki, Furuchi, Sohtaroh, Kurokawa, Kimie, Adachi, Hitomi, Sakaki, Nobuhiro, Tada, Masahiro, Yachi, Akira, Namatame, Kimio, Watanabe, Hiromu, Ohara, Shuichi, Asaki, Shigeru, Yoshino, Junji, Nakazawa, Saburo, Hasegawa, Toshihiro, Suzuki, Shigeru, Nakahara, Akira, Fukutomi, Hisayuki, Yoshimura, Katsunori, Saito, Toshihiko, Harada, Kazumichi, Hayashi, Hideki, Sasako, Mitsuru, Iwasaki, Masaru, Kato, Osamu, Hattori, Kazuhiko, Ariyama, Shigemi, Ohshita, Yoshito, Mimura, Seishiro, Ichii, Makoto, Esaki, Masatoshi, Hiratsuka, Hideo, Nishisaka, Tsuyoshi, Yonekawa, Motoki, Ido, Kenichi, Kimura, Ken, Ito, Yoshiaki, Kasugai, Tatsuzo, Maruyama, Masahiro, Kouzu, Teruo, Hirashima, Toshio, Oguro, Yanao, Ozaki, Masayuki, Imaoka, Wataru, Nishioka, Toshio, Sekiguchi, Toshikazu, Funakoshi, Akihiro, Ibayashi, Hiroshi, Naruse, S., Magee, D. F., Otsuki, Makoto, Ohki, Atsushi, Namba, Mitsuyoshi, Matsuyama, Tatsuo, Kishimoto, Shinya, Imamura, Mikio, Sato, Toshio, Nakaya, S., Saitoh, Y., Kanno, Tomio, Marino, Tetsuya, Okada, Toshikuni, Fujimori, Takahiro, Nagasako, Kou, Ohida, Masahito, Saigenji, Katsunori, Hayakawa, Kazuo, Fukuchi, Sotaro, Asakh, Shigeru, Shibuya, Daisuke, Yambe, Toru, Shibuk, Satoru, Okata, Toshiki, Yoshida, Koichi, Shoji, Tadayoshi, Itch, Shoichiro, Mochizuki, Fukuharu, Hamada, Tsutomu, Yarita, Tadashi, Baba, Yasumasa, Takekoshi, Takeo, Misono, Toshiaki, Nakano, H., Sasaki, K., Misumi, Atsunobu, Akagi, Masanobu, Yamaguchi, Hajime, Yoshida, Shigeaki, Kozawa, Hiroshi, Kawaguchi, Shinpei, Iishi, Hiroyasu, Tatsuta, Masaharu, Takechi, Keishi, Ida, Kazunori, Nomura, Hidehiro, Nishi, Mitsumasa, Yamaguchi, Akihiro, Hachisuka, Kitao, Sakamoto, Kazuhiro, Mori, Katsutaka, Sekoguchi, Tsutomu, Mizumoto, Ryuji, Higashino, Yoshinobu, Nagakawa, Takukazu, Matsuno, Seiki, Sato, Toshio, Imaizumi, Toshihide, Hanyu, Fujio, Sada, Masayuki, Nakayama, Toshimichi, Tajiri, Hisao, Yoshimori, Masayoshi, Katagiri, Kenji, Hayashi, Katsuji, Hamasaki, Keisuke, Mimura, Hisashi, Miyata, Susumu, Shibue, Tadashi, Shimaguchi, Seikoh, Ariyama, Joe, Harima, Kazuo, Asagami, Fumio, Ichikawa, Masafumi, and Naito, Yasuo

Published
1984
Full Text
View/download PDF

49. Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2

Author

Taura, Naota, Ichikawa, Tatsuki, Miyaaki, Hisamitsu, Kadokawa, Yoshiko, Tsutsumi, Takuya, Tsuruta, Shotaro, Kato, Yuji, Inoue, Osami, Kinoshita, Noboru, Ohba, Kazuo, Kato, Hiroyuki, Ohata, Kazuyuki, Masuda, Junichi, Hamasaki, Keisuke, Yatsuhashi, Hiroshi, Nakao, Kazuhiko, Taura, Naota, Ichikawa, Tatsuki, Miyaaki, Hisamitsu, Kadokawa, Yoshiko, Tsutsumi, Takuya, Tsuruta, Shotaro, Kato, Yuji, Inoue, Osami, Kinoshita, Noboru, Ohba, Kazuo, Kato, Hiroyuki, Ohata, Kazuyuki, Masuda, Junichi, Hamasaki, Keisuke, Yatsuhashi, Hiroshi, and Nakao, Kazuhiko

Abstract

Background. HCV infection is associated with lipid disorders because this virus utilizes the host lipid metabolism to sustain its life cycle. Several studies have indicated that higher concentrations of serum cholesterol and LDL before treatment are important predictors of higher rates of sustained virological response (SVR). However, most of these studies involved patients infected with HCV genotype 1. Thus, we performed a multi-institutional clinical study to evaluate the impact of lipid profiles on SVR rates in patients with HCV genotype 2. Methods. A total of 100 chronic hepatitis C patients with HCV genotype 2 who received peg-IFN alfa-2b and ribavirin therapy were consecutively enrolled. The significance of age, sex, BMI, AST level, ALT level, WBC, hemoglobin, platelet count, gamma-glutamyltransferase, total cholesterol level (TC), LDL level, HCV RNA, and histological evaluation was examined for SVR using logistic regression analysis. Results. The 100 patients infected with HCV genotype 2 were divided into 2 groups, an SVR group and a non-SVR group. Characteristics of each group were subsequently compared. There was no significant difference in the level of HCV RNA, BMI, platelet, TG, or stage of fibrosis between the groups. However, there were significant differences in the levels of TC and LDL-C. In multivariate logistic regression analysis using baseline characteristics, high TC level was an independent and significant risk factor (relative risk 18.59, P = 0.015) for SVR. Conclusion. Baseline serum total cholesterol levels should be considered when assessing the likelihood of sustained treatment response following the course of peg-IFN and ribavirin therapy in patients with chronic HCV genotype 2 infection., Gastroenterology Research and Practice, 2012, 317580; 2012

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results